How Does Dulaglutide Work?
How Trulicity works: a GLP-1 linked to an IgG4 antibody fragment for once-weekly dosing. Blood sugar control, appetite effects, and cardiovascular benefits.
Design
GLP-1 + IgG4 Fc fusion
Half-life
~5 days
Receptor target
GLP-1 only
CV reduction
12% MACE (REWIND)
Dosing
Once weekly
Unique Molecular Design
Dulaglutide is engineered by linking a GLP-1 analog to a modified human IgG4 Fc antibody fragment via a small peptide linker. This large molecular structure reduces clearance by the kidneys and DPP-4 enzyme, extending the half-life to approximately 5 days and enabling once-weekly dosing.
The IgG4 fragment was chosen specifically because it doesn't activate the immune system's complement pathway, reducing the risk of injection reactions and immunogenicity. This molecular engineering approach differs from semaglutide's albumin-binding strategy but achieves a similar goal of extended duration.
GLP-1 Receptor Activation
Like all GLP-1 receptor agonists, dulaglutide activates GLP-1 receptors to stimulate glucose-dependent insulin secretion, suppress glucagon release, slow gastric emptying, and reduce appetite. The glucose-dependent mechanism means it only lowers blood sugar when levels are elevated, reducing hypoglycemia risk.
These effects make dulaglutide effective for managing type 2 diabetes while providing secondary benefits of appetite reduction and modest weight loss.
Cardiovascular Protection
The REWIND trial demonstrated that dulaglutide reduces major adverse cardiovascular events by 12% in patients with type 2 diabetes. Notably, REWIND enrolled a broader population with lower baseline cardiovascular risk than other GLP-1 cardiovascular trials, suggesting the benefit may extend to a wider range of diabetes patients.
Frequently Asked Questions
What makes Trulicity different from other GLP-1 medications?
Dulaglutide uses a unique IgG4 antibody fusion design rather than albumin binding or acylation. This provides once-weekly dosing with a hidden-needle pen that's especially easy to use. Its primary distinction is the user-friendly device.
Does Trulicity target the same receptors as Ozempic?
Yes, both target GLP-1 receptors. The difference is in molecular design and potency. Semaglutide (Ozempic) is more potent per milligram and produces greater weight loss, while dulaglutide (Trulicity) is well-tolerated with a unique pen design.
Discuss GLP-1 medication options with a qualified provider
Compare pricing, reviews, and availability across 18,000+ GLP-1 providers nationwide.
Search Providers →Explore all Dulaglutide topics
Cost guides, side effect management, dosing information, insurance coverage, and more — all backed by clinical data.